|
Çູ³ª·¡ ÁÖ½Äȸ»ç |
¿µ¾÷Á÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
[Sexual Healthcare EVE] RA ä¿ë(¾à»ç ¿ì´ë)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
(ÁÖ)±Û·Î¹Ú½º |
(ÁÖ)±Û·Î¹Ú½º °³¹ßÆÀ Á¦Ç° ¼öÀÔ°ü¸®ÀÚ Ã¤¿ë °ø°í
¼¿ï ¸¶Æ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
06.07 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
(ÁÖ)Ææ¹Í½º |
R&D ºÐ¼®¿¬±¸¿ø ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.04 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
06.03 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.01 |
|
|
µ§Ã÷ÇöóÀ̽÷γª |
[¿Ü±¹°è ÀÇ·á±â±â] RA/QA Specialist
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
05.31 |
|
|
(ÁÖ)ºÎ±¹·¦Å×Å© |
ºÎ±¹·¦Å×Å© (Á¤±ÔÁ÷)2021³â ¿µ¾÷Á÷ ½ÅÀÔ/°æ·Â ä¿ë
¼¿ï ¼ººÏ±¸ | °íµîÇб³ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.31 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] BD Assistant ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.27 |
|
|
Àå¿ø¸ÞµðÅØ |
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.27 |
|
|
¼Ò¾ß±×¸°ÅØ |
¼Ò¾ß±×¸°ÅØ Áø´Ü ÀÇ·á±â±â ¹× ¼Ò¸ðÇ° ±¹³»»ç¾÷ºÎ Á÷¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.26 |
|
|
Äܸ޵åÄÚ¸®¾Æ(À¯) |
Medical Education Assistant
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¼ö½Ãä¿ë |
½ÅÀÔ |
ä¿ë½Ã |
05.21 |
|
|
(ÁÖ)Á¦´Ï¾Æ |
ºñÀÓ»ó CRO µ¶¼º ½ÃÇè ¹× ¾àÈ¿ Æò°¡ ´ã´çÀÚ (½ÅÀÔ)
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
½ÅÀÔ |
ä¿ë½Ã |
05.20 |
|